Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
12-1-2019

A novel detrimental homozygous mutation in the WFS1 gene in
two sisters from nonconsanguineous parents with untreated
diabetes insipidus
Dimitrios T Papadimitriou
Athens Medical Center

Kleanthis Kleanthous
Athens Medical Center

Emmanouil Manolakos
Access to Genome

Anatoly Tiulpakov
Endocrinology Research Centre, Moscow

Thomas Nikolopoulos
Attikon University Hospital

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Papadimitriou, Dimitrios T; Kleanthous, Kleanthis; Manolakos, Emmanouil; Tiulpakov, Anatoly;
Nikolopoulos, Thomas; Delides, Alexandros; Voros, Gerasimos; Dinopoulos, Argyrios; Zoupanos, George;
Papadimitriou, Anastasios; Mastorakos, Georgios; and Urano, Fumihiko, ,"A novel detrimental homozygous
mutation in the WFS1 gene in two sisters from nonconsanguineous parents with untreated diabetes
insipidus." Clinical Case Reports. 7,12. . (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8651

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Dimitrios T Papadimitriou, Kleanthis Kleanthous, Emmanouil Manolakos, Anatoly Tiulpakov, Thomas
Nikolopoulos, Alexandros Delides, Gerasimos Voros, Argyrios Dinopoulos, George Zoupanos, Anastasios
Papadimitriou, Georgios Mastorakos, and Fumihiko Urano

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/8651

Received: 20 June 2019
DOI: 10.1002/ccr3.2494

|

Revised: 1 September 2019

|

Accepted: 15 September 2019

CASE REPORT

A novel detrimental homozygous mutation in the WFS1 gene
in two sisters from nonconsanguineous parents with untreated
diabetes insipidus
|

Dimitrios T. Papadimitriou1
Anatoly Tiulpakov
7

Gerasimos Voros

4

|

|

Kleanthis Kleanthous1,2

Thomas Nikolopoulos
8

Argyrios Dinopoulos

Anastasios Papadimitriou

|

5

2

|

|

|

Emmanouil Manolakos3
5,6

Alexandros Delides
9

George Zoupanos

Georgios Mastorakos

10

|

|

|

|

Fumihiko Urano11

1

Department of Pediatric Endocrinology & Diabetes, Athens Medical Center, Athens, Greece

2

Department of Pediatric Endocrinology and Diabetes, Attikon University Hospital, Athens, Greece

3

Access to Genome, Athens‐Thessaloniki, Athens, Greece

4

Department and Laboratory of Inherited Endocrine Disorders, Endocrinology Research Centre, Moscow, Russia

5

Department of Pediatric Otorhinolaryngology, Attikon University Hospital, Athens, Greece

6

Department of Pediatric Otorhinolaryngology, Athens Medical Center, Athens, Greece

7

Department of Pediatric Ophthalmology, Athens Medical Center, Athens, Greece

8

Department of Pediatric Neurology, Attikon University Hospital, Athens, Greece

9

Department of Pediatric Urology, Athens Medical Center, Athens, Greece

10

Endocrine Unit, Aretaieion Hospital, Medical School, University of Athens, Athens, Greece

11

Washington University School of Medicine, St. Louis, MO

Correspondence
Dimitrios T. Papadimitriou, Pediatric
Endocrinologist at Pediatric Endocrine
Clinics, Athens Medical Center, 58, av
Kifisias, Marousi, 15125, Athens, Greece.
Email: dtpapadimitriou@pedoendo.gr

Abstract
Given the limited lifespan and with the recent progress in experimental treatments for
WS, timely diagnosis and multidisciplinary treatment for DI/DM, hydronephrosis,
and visual/psychiatric status—maintaining quality of life—are of crucial importance.
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IN T RO D U C T ION

WS is a rare neurodegenerative disorder. Two sisters, a 19‐
yr blind since 13 (died at 21, due to brain stem atrophy)
and a 7‐yr‐old, from nonconsanguineous parents originated
from Trapezund, had poorly treated DM since 3 years and

untreated DI. Genetic testing revealed a novel homozygous
c.2069G > A mutation in WFS1.
Wolfram syndrome (WS), also called DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness),
is a rare autosomal recessive neurodegenerative genetic disorder.1 The prevalence of WS has been estimated between 1
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in 770 000 in the United Kingdom and 1 in 100 000 in North
America.2 Two causative genes have been identified: WFS1
and CISD2 (WFS2).3 Classical WS is the result of autosomal
recessive mutations affecting the WFS1 gene, which is implicated in endoplasmic reticulum (ER) function,2 although
WS was first described as a mitochondriopathy. However, the
localization of the protein on the endoplasmic reticulum (ER)
membrane challenged this hypothesis. ER contacts mitochondria to ensure effective Ca++ transfer and lipids transfer,
and apoptosis within stabilized and functionalized microdomains, termed “mitochondria‐associated ER membranes”
(MAMs).4 The prognosis of the syndrome is currently poor.
The median age at death is 30 years (range, 25‐49 years), usually from respiratory failure as a result of brain stem atrophy.5
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CA S E RE P O RT

Two sisters from nonconsanguineous parents presented to
our pediatric endocrinology clinic due to severe polyuria‐
polydipsia. They both had poorly treated diabetes mellitus
since the age of 3 years and untreated diabetes insipidus (DI).
A 19‐yr‐old girl totally blind since the age of 13 had primary amenorrhea and bladder incontinence. Cranial nerve
examination was normal except oculomotion with roving eye
movements. Muscle strength was normal with deep tendon reflexes 2/4. There were no signs of ataxia nor extrapyramidal
signs. Mental status was appropriate for age but suffered from
insomnia and apparent depression. Her HbA1c was 8.2%, biochemical values being normal. Gonadotropins in GnRH testing as well as estradiol levels and thyroid function tests were
normal. Abdominal ultrasonography revealed normal uterus
and ovaries but inappropriate for pubertal stage along with
mild (Grade II) hydronephrosis. Comprehensive ophthalmic
examination showed “No Light Perception” in both eyes. The
pupillary light reflex was completely absent, and both pupils
were mid‐dilated. The anterior segment was normal, and the
intraocular pressure was 12 mm Hg in both eyes (Goldman
application tonometer). Dilated fundus examination revealed
complete optic nerve atrophy. Otologic and audiologic evaluation was performed. They included otomicroscopy, tympanometry, transient otoacoustic emissions (TOAE), and automated
auditory brainstem response (aABR). Her tympanogram was
type A, TOAEs “pass” bilateral, as well as aABRs.
The patient had severe salt‐wasting diuresis when treatment
for diabetes insipidus was started,6 and fludrocortisone was
necessary to be added, along with frequent bladder catheterizations for her neurogenic bladder. Six months after appropriate
treatment for diabetes mellitus and insipidus, she had menstrual
onset. Unfortunately, 2 years after presentation, she died unexpectedly in her sleep. Autopsy showed severe brain stem atrophy.
Her 7‐year‐old sister had normal neurological examination. She was prepubertal. Her HbA1c was 10.1%, the rest
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biochemical values being normal. Abdominal ultrasonography revealed mild to severe hydronephrosis (Grade III).
Ophthalmic examination showed a visual acuity 6/15 (0.40
LogMAR) in her right eye and 6/19 (0.50 LogMAR) in her
left eye with + 1.00 diopters sphere corrective lens in both
eyes. The pupillary light reflex was reduced symmetrically in
both eyes, but there was not relative afferent pupillary reflex.
The anterior segment was normal, and the intraocular pressure was 12 mm Hg in the right and 11 mm Hg in the left
eye (Goldman application tonometer). Dilated fundus examination revealed moderate optic nerve atrophy. Otologic and
audiologic tests revealed a type C tympanogram, right side
“pass” and left “fail” of TOAEs, whereas aABRs were “pass”
bilateral.
She also presented severe salt‐wasting diuresis when
treatment for diabetes insipidus was started, and fludrocortisone was necessary to be added for 1 month only, along with
frequent urinary catheterizations for her neurogenic bladder.
On the contrary, we were not able to discontinue fludrocortisone in her sister.
They both normalized their HbA1c (<7%) under intensified multiple insulin daily injections with the 24‐hr analogue
degludec (Tresiba®) and the newest faster formulation of aspart (Fiasp®). Glucose variability was also optimized using
the FlashStyle Libre System, minimizing hypoglycemia and
confining postprandial hyperglycemic excursions. Adjunctive
treatment with idebenone 600 mg × 3 p.o. was given to the
younger sister aiming to visual stabilization7—proven successful for 2.5 years now—while both sisters received additional pioglitazone therapy 45 mg/d × 1 p.o. aiming to
mitigate β‐cell death.8
Genetic testing was performed to confirm the clinical diagnosis of WS. DNA was tested with PCR amplification and
sequencing analysis (Sanger sequencing) of the entire coding
region and all exon‐intron splice junctions of the WFS1 gene
(chromosome 4): reference sequence: NM_006005.3, with
the A of the ATG start codon at position 1. A homozygous
c.2069G > A mutation in WFS1 gene was found in both sisters, whereas the parents were carriers. This point mutation
is a missense mutation in amino acid position 690 (p.C690Y)
replacing cysteine with tyrosine in exon 8. To our knowledge,
this is a novel variant in WFS1 gene, not previously reported
in patients with WS. According to the Prediction Program
PolyPhen‐2, the mutation is predicted to be damaging with a
score of 1000. A different heterozygous—not related to disease manifestation—missense mutation at the same codon
has been reported (690Cys‐ > Arg).

3

|

DISCUSSION

We have previously reported a novel homozygous WFS1 gene
mutation due to maternal uniparental disomy of chromosome
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4.9 Now we present a novel detrimental homozygous WFS1
gene mutation, adding to the genotype‐phenotype correlation
reported so far.10 The two sisters affected were born from
nonconsanguineous parents of Greek descent born in distant regions of Russia. However, detailed genealogical history proved that both originated 5‐6 generations before from
Trapezund, an ancient Greek colony located in the Greek—
until 1922—Pontus, presently in the state of Turkey, indicating a founder mutation effect.
Even though a correct diagnosis of WS had been made
several years ago, none of the girls had ever received treatment for DI. Their diabetes was poorly controlled, and their
quality of life was poor. No care had been ever provided for
their hydronephrosis nor their psychiatric status. Given the
known effect of glycemic control on the neurodegenerative
process 10 and the severe consequences of untreated DI such
as failure to thrive and hydronephrosis, proper treatment
of endocrine dysfunctions is crucial not just to avoid consequences but also to improve quality of survival.11 In our
center, proper multidisciplinary care along with adjunctive
treatment with idebenone 7 and pioglitazone 8,12 has resulted
in stabilization of visual status, resume in growth and pubertal development, normalization of BMI and improved
quality of life in our previously reported patient 9 as well
as the younger of the two sisters currently reported. The
fact that the life span in WS is limited but progress in experimental treatments—that hopefully will be soon widely
available—has been made 13 underlines the importance of
timely diagnosis and effective multidisciplinary approach in
centers with experience in complex endocrine pathologies
such as WS.
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